2022年5月19日 · In this short interview from EuroPCR 22, Prof David Leistner (Charité Universitätsmedizin, DE) joins us on-site to outline the key findings of the CRUZ-HBR registry. This was a real-world study to confirm the outcomes of the Supraflex™ Cruz stent (SMT Ltd) in all-comer patients, where half of the cohort were at high bleeding risk.

2024年10月1日 · The aim of this study was to compare the safety and effectiveness of the ultrathin-strut biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the thin-strut biodegradable-polymer sirolimus-eluting Ultimaster Tansei stent in patients at HBR with abbreviated dual antiplatelet therapy after stenting.

2024年5月14日 · Conclusions In this High Bleeding Risk PCI population with short (median 30 days) DAPT treatment, the Supraflex Cruz stent was non-inferior compared to the Ultimaster Tansei stent Outcomes on target lesion revascularziation and myocardial infarction

Background: The latest generation ultrathin Supraflex Cruz (Sahajanand Medical Technologies Limited, Surat, India) sirolimus-eluting stent (SES) has shown early healing properties and represents an attractive percutaneous coronary intervention (PCI) device in a high bleeding risk (HBR) population.

Cruz HBR Registry is post-market, prospective, multi-center, open-label, single-arm registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease by Percutaneous Coronary Intervention, to confirm the results from TALENT trial.

2023年11月1日 · The Comparison of the Supraflex Cruz 60-µm stent strut versus the Ultimaster Tansei 80-µm stent strut in HBR PCI population (COMPARE 60/80 HBR) study is an investigator-initiated, Dutch multicenter, randomized clinical trial evaluating the safety and efficacy of PCI with the Supraflex Cruz BP-SES as compared with the Ultimaster BP-SES, in ...

In summary, this sub-analysis of the FIRE trial confirms the overall study result in a high-risk HBR subgroup and validates the use of Supraflex Cruz in this highly complex patient population, showing excellent outcomes with complete revascularization even with just one month of dual anti-platelet therapy.

2019年10月14日 · 所有符合无症状缺血、稳定型心绞痛或急性冠状动脉综合征（不稳定型心绞痛和非 STEMI）的患者，符合经皮冠状动脉介入治疗（PCI）的条件，400 名患者必须符合 HBR 标准

2023年11月1日 · Up to 45% of patients who underwent percutaneous coronary intervention (PCI) may have a high bleeding risk (HBR), depending on the bleeding risk definition. 1 This condition is often associated with an enhanced risk of thrombotic events with a negative impact on short- and long-term outcomes, 2-8 making the choice of an appropriate ...

The Cruz-HBR Registry was a prospective, multi-center, single-arm registry to evaluate the safety and efficacy of Supraflex Cruz stent in the treatment of all-comer patients treated with PCI. The study evaluated a total of 1200 patients with around 400 HBR patients.